Hence, we propose that peptides/peptidomimetics could compensate the FMRP deficiency restoring the imbalance of protein synthesis and actin dynamics, suggesting a new and promising strategy for treating FXS. The gene discussed is FMR1; the disease is fragile X syndrome.